• ProMIS Neurosciences appointed Ivana Rubino as chief commercial officer, effective Oct. 5, 2026.
• Rubino most recently served at Biogen as vice president, global head of Alzheimer’s disease and multiple sclerosis medical.
• Earlier roles included senior leadership posts at Biogen across Alzheimer’s programs, with prior medical affairs and commercial roles at Roche.
• Rubino will lead commercial strategy and market preparation for PMN310, including market access planning and launch readiness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060705PRIMZONEFULLFEED9840064) on October 06, 2026, and is solely responsible for the information contained therein.